ADAM17 and glioblastoma: A negative correlation has been found in glioblastoma between the genetic signature of the epithelial-to-mesenchymal transition (EMT) and that of CD133 [33], suggesting that ADAM10 and ADAM17 inhibition might activate the transition, differentiating the cells and increasing cell migration and invasion.